초록 ▼

A method of providing a therapeutic, diagnostic or lubricious hydrophilic coating on an intracorporeal medical device and the coated device produced thereby, wherein the coating is durable. In one embodiment, the coating comprises a polymerized base coat and a therapeutic, diagnostic or hydrophilic

A method of providing a therapeutic, diagnostic or lubricious hydrophilic coating on an intracorporeal medical device and the coated device produced thereby, wherein the coating is durable. In one embodiment, the coating comprises a polymerized base coat and a therapeutic, diagnostic or hydrophilic top coat, where the base coat has a binding component which binds to the top coat, and a grafting component which binds to the binding component and adheres to the device. In another embodiment, the coating comprises a blend of a hydrophilic compound, a grafting component, and salt, wherein the polymerized grafting component contains uncrosslinked domains. The coating of the invention may be applied to a medical device with a polymeric surface such as a polymeric catheter, or a metal device coated with a polymeric primer or without a primer, or to a stent.

대표청구항 ▼

A method of providing a therapeutic, diagnostic or lubricious hydrophilic coating on an intracorporeal medical device and the coated device produced thereby, wherein the coating is durable. In one embodiment, the coating comprises a polymerized base coat and a therapeutic, diagnostic or hydrophilic

A method of providing a therapeutic, diagnostic or lubricious hydrophilic coating on an intracorporeal medical device and the coated device produced thereby, wherein the coating is durable. In one embodiment, the coating comprises a polymerized base coat and a therapeutic, diagnostic or hydrophilic top coat, where the base coat has a binding component which binds to the top coat, and a grafting component which binds to the binding component and adheres to the device. In another embodiment, the coating comprises a blend of a hydrophilic compound, a grafting component, and salt, wherein the polymerized grafting component contains uncrosslinked domains. The coating of the invention may be applied to a medical device with a polymeric surface such as a polymeric catheter, or a metal device coated with a polymeric primer or without a primer, or to a stent. Oct. 1984. Kast et al., "Role of HLA-A motifs in identification of potential CTL epitopes in human papillmavirus type 16 E6 and E7 proteins," J. Immunol. 152:3904-3912, 1994. Kawakami et al., "Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression," J. Immunol. 154:3961-3968, 1995. Maeda et al., "Serum antibody reacting with placental syncytiotrophoblast in sera of patients with autoimmune diseases--a possible relation to type C RNA retroviruses," Clin. Exp. Immunol. 60:645-653, 1985. Margalit et al., "Prediction of immunodominant helper T cell antigenic sites from the primary sequence," The Journal of Immunology 138(7):2213-2229, Apr. 1, 1987. McCombs, R., "Role of oncornaviruses in carcinoma of the prostate," Cancer Treatment Reports 61(2):131-132, Mar./Apr. 1977. Porter-Jordan and Lippman et al., "Overview of the biologic markers of breast cancer," Breast Cancer 8(1):73-100, Feb. 1994. Rammensee et al., "MHC ligands and peptide motifs: first listing," Immunogenetics 41:178-228, 1995. Rothbard and Taylor, "A sequence pattern common to T cell epitopes," The EMBO Journal 7(1):93-100, Jan. 1988. Sette et al., "The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes," J. Immunol. 153:5586-5592, 1994. Smith et al., "Expression of antigenic crossreactivity to RD114 p30 protein in a human fibrosarcoma cell line," Proc. Natl. Acad. Sci. USA 74(2):744-748, Feb. 1977. Spouge et al., "Strong conformational propensities enhance T cell antigenicity," The Journal of Immunology 138(1):204-212, Jan. 1987. Tsai et al., "In vitro immunization and expansion of antigen-specific cytotoxic T-lymphocytes for adoptive immunotherapy using peptide pulsed dendritic cells," Critical Reviews in Immunology 18:65-75, 1998. Vaczi and Toth, "Studies on antigens of C-type p